As of January 22, 2025, Keros Therapeutics (KROS) has a market cap of $0.46 billion USD. According to our data, Keros Therapeutics is ranked No.6221 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.46 B |
-28.05%
|
Dec 31, 2024 | $0.64 B |
-60.19%
|
Dec 29, 2023 | $1.61 B |
-17.20%
|
Dec 30, 2022 | $1.95 B |
-17.93%
|
Dec 31, 2021 | $2.37 B |
-17.05%
|
Dec 31, 2020 | $2.86 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
FibroGen
FGEN
|
$50.79 M |
0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
uniQure
QURE
|
$0.82 B |
0.000 M
|
Netherlands
|
Rocket Pharmaceuticals
RCKT
|
$1.11 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Ultragenyx
RARE
|
$3.97 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Market Cap | = | KROS Stock Price | * | KROS Shares Outstanding |
= | $11.39 | * | 40.51 M | |
= | $0.46 B |